摘要
目的研究肾康注射液联合缬沙坦治疗早期糖尿病肾病患者的临床疗效及其对血清同型半胱氨酸、转化生长因子β1、炎性因子(超敏C反应蛋白及白细胞介素6)表达水平的影响。方法选取糖尿病。肾病患者138例,采用随机数字表法分为对照组和治疗组,对照组采用口服缬沙坦降压等常规治疗,治疗组在对照组治疗基础上加用肾康注射液,比较分析两组患者的总体疗效、血糖指数与肾功能改善情况、血清同型半胱氨酸、转化生长因子β1水平及炎性因子表达的情况。结果治疗后治疗组总有效率(91.30%)明显高于对照组(76.81%),差异有统计学意义(χ^2=5。004,P〈0.05);与对照组治疗后比较,治疗组患者空腹血糖、餐后2h血糖、糖化血红蛋白、尿白蛋白排泄率、胱抑素C、血肌酐浓度均显著降低,差异均有统计学意义(t=4.514、3.743、4.754、6.214、3.925、3.777,均P〈0.05);与对照组治疗后比较,血清同型半胱氨酸、转化生长因子β1、炎性因子超敏C反应蛋白及白细胞介素6表达水平也明显下降[(11.78±1.95)μmol/L比(9.21±1.64)μmol/L,(71.32±14.88)mg/L比(60.04±11.75)mg/L,(7.07±1.25)mg/L比(5.81±1.14)mg/L,(50.24±21.86)pg/mL比(32.55±17.01)pg/mL],差异均有统计学意义(t=8.378、4.942、6.187、5.305,均P〈0.05)。结论肾康注射液联合缬沙坦治疗糖尿病肾病患者效果显著,改善患者肾功能,降低血糖,可能与抑制炎性因子表达及降低同型半胱氨酸、转化生长因子β1水平有关。
Objective To study the clinical effect of Shenkang injection combined with valsartan in the treat- ment of patients with early stage diabetic nephropathy, and its influence on the expression changes of homocysteinc (Hey) ,transforming growth factor β1 (TGF-β1) the inflammatory cytokines high sensitive C -reactive protein (hs -CRP), and interleukin -6 (IL- 6). Methods 138 cases of early stage diabetic nephropathy were randomly divided into control group (conventional treatment, valsartan act as antihypertensive drug) and treatment group (treated with Shenkang injection combined with valsartan) by digital table. The total effective rate ,glyeemic index, renal function, levels of Hey and TGF - β1, expression levels of inflammatory cytokines of two groups were compared. Results The total effective rate of the treatment group (91.30%) was significantly higher than the control group ( 76.81% ) (χ^2= 5. 004, P 〈 0.05 ). The values of FPG,2h PG, HbAlc, UAER, CysC and Scr were lower in the treat- ment group compared with the control group (t=4. 514,3. 743,4. 754,6. 214,3. 925,3. 777, all P 〈 0.05 ). Compared with the control group, the concentrations of Hcy, TGF - β1, hs - CRP and IL -6 decreased significantly[ ( 11. 78±1.95 ) txmol/L vs (9.21 ± 1.64) μmol/L, ( 71.32 ± 14.88 ) mg/L vs ( 60.04±11.75 ) mg/L, ( 7.07± 1.25 mg/L vs (5.81±1.14) mg/L, (50.24 ±21.86) pg/mL vs ( 32.55 ± 17.01 ) pg/mL], the differences were statistically significant (t = 8. 378,4. 942,6. 187,5. 305, all P 〈 0.05 ). ConcluSion Shenkang injection eombined Kith valsartan for the treatment of early stage diabetic nephropathy has significant clinical efficacy. It can improve patients're- nal function and reduce blood sugar levels. The effects may be related with inflammatory response inhibition and Hey, TGF - β1 levels reduction.
出处
《中国基层医药》
CAS
2016年第6期911-914,共4页
Chinese Journal of Primary Medicine and Pharmacy
关键词
肾康注射液
糖尿病肾病
转化生长因子Β1
炎性因子
临床疗效
Shenkang injectiQn
Diabetic nephropathy
Transforming growth factor β1
Inflammatoryfactor
Clinical efficacy